Neurodegeneration is an important determinant of disability in multiple sclerosis (MS) but while currently approved treatments reduce inflammation, they have not been shown to reduce neurodegeneration. SIRT1, a NAD dependent protein deacetylase, has been implicated in the pathogenesis of neurodegeneration in neurological diseases including MS. We have studied the role of SIRT1 in experimental autoimmune encephalomyelitis (EAE) and found evidence for a neuroprotective role. In this review we summarize the most recent findings from the use of SIRT1 activators and SIRT1 overexpression in transgenic mice. These data support provide a rational for the use of SIRT1 activators in MS.
Neurodegeneration in multiple sclerosis
Neurodegeneration has become the focus of research into multiple sclerosis (MS) therapy because currently approved drugs, while reducing inflammation, have not eliminated neurodegeneration which appears linked to progressive disease and disability (Noseworthy et al., 2000) . Pathologically, MS is characterized by both white matter and gray matter inflammation (Bo et al., 2003; Cifelli et al., 2002; Dutta and Trapp, 2007; Stadelmann et al., 2011; Steinman et al., 2002) which is believed to be initiated by autoreactive T cells activated in the periphery (Steinman et al., 2002) . These cells are thought to migrate across the blood brain barrier where they recruit lymphocytes and monocytes, activate microglia, and stimulate the deposition of immunoglobulins and complement inducing a hypoxia-like insult (Henderson et al., 2009; Lucchinetti et al., 2000) . Neurodegeneration appears to occur early in the disease process and be linked to the inflammatory process (Frischer et al., 2009; Magliozzi et al., 2010) . Most of the current disease modifying therapies in MS reduce inflammation and the number of clinical relapses but do not prevent neurodegeneration or the development of progressive disease suggesting that the neurodegeneration is not dependent on ongoing inflammation. This has led to a search for new therapies for MS that are neuroprotective.
Mitochondrial changes in MS
Mitochondrial dysfunction with reduced nicotinamide dinucleotide (NAD+) appears to play a role in neurodegeneration in MS pathogenesis (Campbell et al., 2012 (Campbell et al., , 2014 Carvalho, 2013; Kalman et al., 2007; Lassmann et al., 2012; Lu et al., 2000; Mao and Reddy, 2010; Penberthy and Tsunoda, 2009; Witte et al., 2010; Zambonin et al., 2011) . Mitochondrial damage, triggered by inflammation may play a role in demyelination and neurodegeneration (Lassmann et al., 2012) . The discovery of mitochondrial abnormalities in MS has led to the hypothesis that mitochondrial dysfunction may lead to impaired oxidative energy metabolism in the neuron resulting in an inability to maintain neuronal and axonal function and integrity, leading to axonal degeneration and/or neuronal death (Su et al., 2009; van et al., 2012; Witte et al., 2010) . Neuropathological studies on experimental re-myelination in vivo showed an increase in mitochondrial content in re-myelinated axons which was associated with an increase in mitochondrial respiratory chain complex IV activity (Campbell et al., 2012 (Campbell et al., , 2014 Zambonin et al., 2011) . A significant increase in the number of stationary mitochondria was seen in re-myelinated axons compared with myelinated and demyelinated axons in In vitro studies (Campbell et al., 2012 (Campbell et al., , 2014 Zambonin et al., 2011) . It has been further suggested that inflammation may induce oxidative stress-related mitochondrial DNA deletions in neurons, which could contribute to neurodegeneration in MS (Campbell et al., 2014; Campbell and Mahad, 2012) . In chronic MS lesions, a decline of energy metabolism in affected cells resulting in decreased ATP synthesis could ultimately lead to degeneration and cell Journal of Neuroimmunology 304 (2017) 29-34 
